عرض بسيط للتسجيلة

المؤلفSoliman, Alaa Bahaa Eldeen
المؤلفPawluk, Shane Ashley
المؤلفWilby, Kyle John
المؤلفRachid, Ousama
تاريخ الإتاحة2021-11-08T05:12:30Z
تاريخ النشر2021-10-20
اسم المنشورJournal of Clinical Pharmacy and Therapeutics
المعرّفhttp://dx.doi.org/10.1111/jcpt.13543
الاقتباسSoliman, ABE, Pawluk, SA, Wilby, KJ, Rachid, O. Creation of an inventory of quality markers used to evaluate pharmacokinetic literature: A systematic review. J Clin Pharm Ther. 2021; 00: 1– 6. https://doi.org/10.1111/jcpt.13543
الرقم المعياري الدولي للكتاب0269-4727
معرّف المصادر الموحدhttp://hdl.handle.net/10576/24859
الملخصWhat is known and objective: Robust critical appraisal tools for clinical pharmacokinetic studies are limited. Before development of such a tool is possible, quality markers (items deemed important for credibility of study results) must be identified. We aim to create an inventory of quality markers intended for the appraisal of clinical pharmacokinetic studies and to categorize identified markers into associated domains of study quality. Methods: Medline via ProQuest central (1946–Sep 2020, EMBASE (1974–Sep 2020), Cochrane database of systematic reviews, Google and Google Scholar were searched using the following search categories: pharmacokinetics, reporting guidelines and quality markers. Reference lists of the identified articles were searched manually. Any article (review, study or guideline) reporting quality markers related to the appraisal of pharmacokinetic literature was eligible for inclusion. Articles were further screened and limited to those reported in English on human subjects only. Cell-based and animal-based pharmacokinetic studies were excluded. Extracted data from included articles included identified or perceived markers of quality and baseline article data. Identified quality markers were then categorized according to manuscript reporting domains (abstract, introduction/background, methodology, results, discussion and conclusion). Results and discussion: Of 789 studies identified, 17 articles were included for extraction of quality markers. A total of 35 quality markers were identified across eight categories. The most frequently reported quality markers were related to method (13/35) and result sections (6/35). Quality markers encompassed all aspects of study design and reporting and were both similar and different to established reporting checklists for clinical pharmacokinetic studies. What is new and conclusion: The inventory of quality markers is now suitable to undergo further testing for inclusion in a tool designed for the appraisal of clinical pharmacokinetic studies.
اللغةen
الناشرWiley
الموضوعclinical pharmacokinetics
critical appraisal
pharmacokinetics
quality markers
reporting checklist
العنوانCreation of an inventory of quality markers used to evaluate pharmacokinetic literature: A systematic review
النوعArticle Review
الصفحات1-6
ESSN1365-2710
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة